JENNIFER BLACKMON: Open Payments
NPI 1417583642 · GRANTS PASS, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$263 in 13 payments from 8 companies in 2025. Trend: 2023 $42 · 2024 $58 · 2025 $263
Food & beverage: $263
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 3 | $58 |
| Novo Nordisk Inc | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| RECORDATI_RARE_DISEASES_INC. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
Products named: Yorvipath, Ozempic, REXULTI, ISTURISA, INSPIRE, TRINTELLIX, Livmarli, MOUNJARO.
Industry payments across OR — which companies pay providers there.
